Currently browsing tag


PSivida Corp says experimental eye drug meets study goal

(Reuters) – Drugmaker pSivida Corp said its experimental eye drug prevented inflammation in the back of patients’ eyes in a late-stage study. The drugmaker said only 18.4 percent of the patients given the treatment Medidur had the condition, posterior uveitis, return, compared with 78.6 percent patients who were given placebo. The company’s shares were up 32.4 percent at $4.90 in premarket trading on Tuesday. (Reporting by Vidya L Nathan in Bengaluru; Editing by Shounak Dasgupta)

For some elderly, unclogging leg arteries doesn’t improve mobility

By Andrew M. Seaman (Reuters Health) – For nursing home residents, surgery to improve blood flow to the legs yields only limited improvements in mobility, according to a new study. Knowing that so-called lower extremity revascularization may not improve mobility allows doctors, patients and families to have more realistic discussions about outcomes of the operation, said Dr. Emily Finlayson, the study’s senior author from the Philip R. Lee Institute for Health Policy Studies at the University of California, San Francisco. The nearly 11,000 nursing home residents in the study had a problem called peripheral artery disease, which results when arteries in the legs are clogged and blood flow is reduced. To treat the condition, the residents underwent lower extremity revascularization between 2005 and 2009, at an average age of 82.